Medlab granted approval for two cannabis trials

Company News

by Jessica Amir

Medlab Clinical Limited (ASX:MDC) has been granted approval for two different cannabis based human trials. It was granted approval by the Human Research Ethics Committee.

The medical research and development company says the patent pending medicines, NanaBis and NanaBidial, have two different applications and will be clinically tested at different locations.

The company NanaBis trial will be conducted at the Royal North Shore Hospital’s Northern Cancer Centre on advanced stage cancer patients with intractable pain.

Medlab says the trials mark a significant breakthrough for Australian medicine and are a massive advancement in global cannabis research

Both trials are expected to commence shortly.

Shares in Medlab Clinical Limited (ASX:MDC) are trading 0.63 per cent higher to 80 cents.

Jessica Amir

Finance News Network
Jessica is a senior finance journalist and presents bulletins including the Market Outlook, Market at Midday and Market Wrap. She also interviews ASX CEOs and leading fund managers. She joined FNN in January 2017 with over six years of broadcast journalism experience including with Sky News Business, ABC 1, ABC's The Business and ABC24. She’s also worked as a TV reporter for Prime 7 and WIN News. Jessica has worked in financial planning for over six years with leading wealth managers and in real estate.